BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

689 related articles for article (PubMed ID: 38473776)

  • 1. Glioblastoma Therapy: Past, Present and Future.
    Obrador E; Moreno-Murciano P; Oriol-Caballo M; López-Blanch R; Pineda B; Gutiérrez-Arroyo JL; Loras A; Gonzalez-Bonet LG; Martinez-Cadenas C; Estrela JM; Marqués-Torrejón MÁ
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Therapies in Glioblastoma Treatment: Review of Glioblastoma; Current Treatment Options; and Novel Oncolytic Viral Therapies.
    Shah S
    Med Sci (Basel); 2023 Dec; 12(1):. PubMed ID: 38249077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
    Lefranc F; Rynkowski M; DeWitte O; Kiss R
    Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.
    Kardani K; Sanchez Gil J; Rabkin SD
    Front Cell Infect Microbiol; 2023; 13():1206111. PubMed ID: 37325516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
    Suryawanshi YR; Schulze AJ
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
    Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
    Front Immunol; 2019; 10():2683. PubMed ID: 31798595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of glioblastoma: Recent advances and future prospects.
    Yuan B; Wang G; Tang X; Tong A; Zhou L
    Hum Vaccin Immunother; 2022 Nov; 18(5):2055417. PubMed ID: 35344682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma.
    Strecker MI; Wlotzka K; Strassheimer F; Roller B; Ludmirski G; König S; Röder J; Opitz C; Alekseeva T; Reul J; Sevenich L; Tonn T; Wels WS; Steinbach JP; Buchholz CJ; Burger MC
    Oncoimmunology; 2022; 11(1):2127508. PubMed ID: 36249274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging therapies for glioblastoma: current state and future directions.
    Rong L; Li N; Zhang Z
    J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights in the immunobiology of glioblastoma.
    Strepkos D; Markouli M; Klonou A; Piperi C; Papavassiliou AG
    J Mol Med (Berl); 2020 Jan; 98(1):1-10. PubMed ID: 31650201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
    Verdugo E; Puerto I; Medina MÁ
    Cancer Commun (Lond); 2022 Nov; 42(11):1083-1111. PubMed ID: 36129048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local immunotherapy of glioblastoma: A comprehensive review of the concept.
    Sabahi M; Salehipour A; Bazl MSY; Rezaei N; Mansouri A; Borghei-Razavi H
    J Neuroimmunol; 2023 Aug; 381():578146. PubMed ID: 37451079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sonodynamic therapy and magnetic resonance-guided focused ultrasound: new therapeutic strategy in glioblastoma.
    Bonosi L; Marino S; Benigno UE; Musso S; Buscemi F; Giardina K; Gerardi R; Brunasso L; Costanzo R; Iacopino DG; Maugeri R
    J Neurooncol; 2023 May; 163(1):219-238. PubMed ID: 37179515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma.
    Annovazzi L; Mellai M; Schiffer D
    Cancers (Basel); 2017 May; 9(6):. PubMed ID: 28587121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
    Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
    Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Glioblastoma Therapy: An Update on Current Approaches.
    Angom RS; Nakka NMR; Bhattacharya S
    Brain Sci; 2023 Oct; 13(11):. PubMed ID: 38002496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
    Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J
    Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.